miravirsen: has antiviral activity; a 15-nucleotide locked nucleic acid-modified antisense oligonucleotide that inhibits miR-122 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 56843415 |
| MeSH ID | M0584885 |
| Synonym |
|---|
| rna, (p-thio)((2'-o,4'-c-methylene)m5c-dc-(2'-o,4'-c-methylene)a-dt-dt-(2'-o,4'-c-methylene)g-(2'-o,4'-c-methylene)m5u-dc-da-(2'-o,4'-c-methylene)m5c-da-(2'-o,4'-c-methylene)m5c-dt-(2'-o,4'-c-methylene)m5c-(2'-o,4'-c-methylene)m5c) |
| unii-q083ajw7vs |
| 1072874-90-8 |
| spc3649 parent acid |
| miravirsen |
| miravirsen [inn] |
| q083ajw7vs , |
| spc-3649 |
Miravirsen is a locked nucleic acid-modified DNA phosphorothioate antisense oligonucleotide. It sequesters mature miR-122 in a highly stable heteroduplex, thereby inhibiting its function.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Miravirsen is a locked nucleic acid-modified DNA phosphorothioate antisense oligonucleotide that sequesters mature miR-122 in a highly stable heteroduplex, thereby inhibiting its function." | ( Treatment of HCV infection by targeting microRNA. Chen, A; Hodges, MR; Janssen, HL; Kauppinen, S; King, BD; Lawitz, EJ; Levin, AA; Patel, K; Patick, AK; Persson, R; Reesink, HW; Rodriguez-Torres, M; van der Meer, AJ; Zeuzem, S; Zhou, Y, 2013) | 1.11 |
| "Miravirsen is a β-D-oxy-locked nucleic acid-modified phosphorothioate antisense oligonucleotide targeting the liver-specific microRNA-122 (miR-122). " | ( In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122. Hodges, MR; Ottosen, S; Parsley, TB; Patick, AK; Raney, AK; van der Veer, E; van Doorn, LJ; Yang, L; Zeh, K, 2015) | 2.09 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Targeting miR-122 may be an effective and safe treatment strategy for HCV infection and should be investigated in larger clinical trials." | ( Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients. de Bruijne, J; Hodges, MR; Janssen, HL; Kupcova, V; Lawitz, EJ; Maan, R; Reesink, HW; Rodriguez-Torres, M; van der Meer, AJ; van der Ree, MH; van Vliet, A; Welzel, TM; Wiercinska-Drapalo, A; Zeuzem, S, 2014) | 0.4 |
Plasma levels of 179 miRNAs were determined by qPCR and compared between patients dosed with miravirsen or placebo. At week 1, 4, 6 and 10/12, patients had respectively a median 72-fold, 174-fold,. 1109-fold and 552-fold lower expression of miR-122 than at baseline. SVR was achieved in 7/12 patients previously dosing with mirvirsen.
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 19 (95.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (35.52) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (19.05%) | 5.53% |
| Reviews | 8 (38.10%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (42.86%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||